SCHEMBL6440063

SCHEMBL6440063

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CC[C@@H](c2cccc(C(F)(F)F)c2)[C@@H](c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 1/20 0.50
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
HSD11B1 P28845 1/20 0.47
RHOA P61586 4/20 0.47
TACR1 P25103 2/20 0.47
RHOC P08134 1/20 0.47
MGLL Q99685 1/20 0.47
CYP3A4 P08684 2/20 0.47
TSHR P16473 1/20 0.47
CCR2 P41597 3/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ATM Q13315 1/20 0.46
EPHX2 P34913 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440065 1.00 RBP4 (0.50) RBP4LMNAPOLBHPGDHSD11B1
SCHEMBL6441435 0.94 RHOA (0.51) RHOATACR1RHOCCYP3A4TSHR
SCHEMBL6441438 0.94 RHOA (0.51) RHOATACR1RHOCCYP3A4TSHR
SCHEMBL6442803 0.90 RHOA (0.52) RHOATACR1RHOCMGLLCYP3A4
SCHEMBL5918275 0.90 RHOA (0.45) RBP4RHOATACR1RHOCCYP3A4
SCHEMBL5918276 0.90 RHOA (0.45) RBP4RHOATACR1RHOCCYP3A4
SCHEMBL6442802 0.90 RHOA (0.52) RHOATACR1RHOCMGLLCYP3A4
SCHEMBL7236786 0.89 RHOA (0.50) RHOATACR1RHOCUSP2
SCHEMBL7236789 0.89 RHOA (0.50) RHOATACR1RHOCUSP2
SCHEMBL6439778 0.88 RHOC (0.59) RHOATACR1RHOCMGLLCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1360184-B1 PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-03-30 EP disclosed
EP-1360184-A1 PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-11-12 EP disclosed
US-6642226-B2 Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors HOFFMAN-LA ROCHE INC. 2003-11-04 US disclosed
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds F.HOFFMANN-LA ROCHE AG (CH) 2002-10-17 US disclosed
WO-2002062784-A1 PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds TACR1, OPRK1, TACR2 RBP4 2482/4885LMNA 4122/4885POLB 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.